Tectonic Therapeutic Inc. (TECX)
NASDAQ: TECXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TECX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $405.26M
- EPS (TTM)
- -$4.63
- Dividend yield
- None
- 52-week range
- 16.77 – 39.53
- Day range
- 20.41 – 21.57
- Volume / Avg
- 268.83K / 212.16K
- Beta
- —
- Shares outstanding
- 19.55M
52-week range
TECX stock today
Shares of Tectonic Therapeutic (TECX) finished lower on Nov 20 at $20.73, a drop of 1.47% or $0.31 per share, versus the S&P 500's 3.70% decline. At this level, TECX sits near the bottom of its 52-week range of $16.77 to $39.53: 47.6% below the high, set on Jul 6, 2026 and 23.6% above the low. TECX is down 0.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.1%.
Tectonic Therapeutic has posted a net loss over the last twelve months (EPS of -$4.63), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tectonic Therapeutic
Company profileTectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Alise S. Reicin M.D., Ph.D.
- Headquarters
- Watertown, MA
- Employees
- 60
- IPO year
- 2018
- Website
- tectonictx.com
Financial highlights
Full financialsTectonic Therapeutic reported a net loss of $74.2 million, compared with a loss of $58.0 million a year earlier. Diluted earnings per share came in at -$4.05.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-74.15M | $-57.98M | $-42.82M | $-105.89M | $-119.13M |
| EPS (diluted) | $-4.05 | $-6.83 | $-33.76 | $-2.42 | $-2.78 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$71.00+242.50%
- Strong buy 1
- Buy 8
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.08 vs $-1.38
- Surprise
- +21.74%
TECX news
All TECX newsTectonic Therapeutic peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TVGNTevogen Inc. | 5.90 | -6.35% | $405.20M | vs TECX |
| CADLCandel Therapeutics Inc. | 5.04 | -1.75% | $395.37M | vs TECX |
| PROKProKidney Corp. Class A | 1.04 | -1.89% | $415.21M | vs TECX |
| IRLAIRulya Therapeutics Inc. | 39.88 | -0.15% | $432.36M | vs TECX |
| FENCFennec Pharmaceuticals Inc. | 13.09 | -2.68% | $462.14M | vs TECX |
| ALECAlector Inc. | 2.34 | +1.52% | $347.63M | vs TECX |
| RGNXREGENXBIO Inc. | 7.16 | -0.28% | $473.44M | vs TECX |
| SANASana Biotechnology Inc. | 1.59 | -8.62% | $476.42M | vs TECX |
Indexes, lists and sector
Tectonic Therapeutic stock FAQ
What is Tectonic Therapeutic's stock price today?
TECX last traded at $20.73 as of Nov 20, 4:00 PM EST, down 1.47% on the day. Prices are delayed at least 15 minutes.
Does Tectonic Therapeutic pay a dividend?
No. Tectonic Therapeutic does not currently pay a regular cash dividend.
Who is Tectonic Therapeutic's CEO?
Dr. Alise S. Reicin M.D., Ph.D. is the chief executive officer of Tectonic Therapeutic Inc., which has about 60 employees.
Has TECX ever split its stock?
Yes. The most recent TECX stock split was a 1-for-12 split on Jun 21, 2024.
What is the TECX 52-week high?
The 52-week high for TECX is $39.53 and the 52-week low is $16.77. The stock is currently 47.6% below its high.